215 related articles for article (PubMed ID: 17475686)
1. The cost effectiveness of opportunistic chlamydia screening in England.
Adams EJ; Turner KM; Edmunds WJ
Sex Transm Infect; 2007 Jul; 83(4):267-74; discussion 274-5. PubMed ID: 17475686
[TBL] [Abstract][Full Text] [Related]
2. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland.
Gillespie P; O'Neill C; Adams E; Turner K; O'Donovan D; Brugha R; Vaughan D; O'Connell E; Cormican M; Balfe M; Coleman C; Fitzgerald M; Fleming C
Sex Transm Infect; 2012 Apr; 88(3):222-8. PubMed ID: 22213681
[TBL] [Abstract][Full Text] [Related]
3. Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.
Hu D; Hook EW; Goldie SJ
Ann Intern Med; 2004 Oct; 141(7):501-13. PubMed ID: 15466767
[TBL] [Abstract][Full Text] [Related]
4. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women.
Gift TL; Gaydos CA; Kent CK; Marrazzo JM; Rietmeijer CA; Schillinger JA; Dunne EF
Sex Transm Dis; 2008 Nov; 35(11 Suppl):S66-75. PubMed ID: 18830137
[TBL] [Abstract][Full Text] [Related]
5. Cost and effectiveness of Chlamydia screening among male military recruits: Markov modeling of complications averted through notification of prior female partners.
Nevin RL; Shuping EE; Frick KD; Gaydos JC; Gaydos CA
Sex Transm Dis; 2008 Aug; 35(8):705-13. PubMed ID: 18461015
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project.
Roberts TE; Robinson S; Barton PM; Bryan S; McCarthy A; Macleod J; Egger M; Low N
BMJ; 2007 Aug; 335(7614):291. PubMed ID: 17656504
[TBL] [Abstract][Full Text] [Related]
7. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Coutinho RA; Jager JC
Ned Tijdschr Geneeskd; 1999 Mar; 143(13):677-81. PubMed ID: 10321301
[TBL] [Abstract][Full Text] [Related]
8. Establishing the National Chlamydia Screening Programme in England: results from the first full year of screening.
LaMontagne DS; Fenton KA; Randall S; Anderson S; Carter P
Sex Transm Infect; 2004 Oct; 80(5):335-41. PubMed ID: 15459399
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens.
van Valkengoed IG; Postma MJ; Morré SA; van den Brule AJ; Meijer CJ; Bouter LM; Boeke AJ
Sex Transm Infect; 2001 Aug; 77(4):276-82. PubMed ID: 11463928
[TBL] [Abstract][Full Text] [Related]
10. Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in The Netherlands.
de Wit GA; Over EA; Schmid BV; van Bergen JE; van den Broek IV; van der Sande MA; Welte R; Op de Coul EL; Kretzschmar ME
Sex Transm Infect; 2015 Sep; 91(6):423-9. PubMed ID: 25759475
[TBL] [Abstract][Full Text] [Related]
11. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.
Howell MR; Quinn TC; Gaydos CA
Ann Intern Med; 1998 Feb; 128(4):277-84. PubMed ID: 9471930
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection.
Low N; McCarthy A; Macleod J; Salisbury C; Campbell R; Roberts TE; Horner P; Skidmore S; Sterne JA; Sanford E; Ibrahim F; Holloway A; Patel R; Barton PM; Robinson SM; Mills N; Graham A; Herring A; Caul EO; Davey Smith G; Hobbs FD; Ross JD; Egger M;
Health Technol Assess; 2007 Mar; 11(8):iii-iv, ix-xii, 1-165. PubMed ID: 17311735
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of economics and acceptability of screening for Chlamydia trachomatis infection, in women attending antenatal, abortion, colposcopy and family planning clinics in Scotland, UK.
Norman JE; Wu O; Twaddle S; Macmillan S; McMillan L; Templeton A; McKenzie H; Noone A; Allardice G; Reid M
BJOG; 2004 Nov; 111(11):1261-8. PubMed ID: 15521872
[TBL] [Abstract][Full Text] [Related]
14. What is the cost of pelvic inflammatory disease and how much could be prevented by screening for chlamydia trachomatis? Cost analysis of the Prevention of Pelvic Infection (POPI) trial.
Aghaizu A; Adams EJ; Turner K; Kerry S; Hay P; Simms I; Oakeshott P
Sex Transm Infect; 2011 Jun; 87(4):312-7. PubMed ID: 21444333
[TBL] [Abstract][Full Text] [Related]
15. Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals.
Smith KJ; Cook RL; Roberts MS
Value Health; 2007; 10(5):358-66. PubMed ID: 17888100
[TBL] [Abstract][Full Text] [Related]
16. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
Ruitenberg EN
Ned Tijdschr Geneeskd; 1999 May; 143(19):1012. PubMed ID: 10368724
[No Abstract] [Full Text] [Related]
17. Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease.
Howell MR; Gaydos JC; McKee KT; Quinn TC; Gaydos CA
Sex Transm Dis; 1999 Oct; 26(9):519-26. PubMed ID: 10534206
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of the Chlamydia Monday--a community-based intervention to decrease the prevalence of chlamydia in Sweden.
Deogan CL; Bocangel MK; Wamala SP; Månsdotter AM
Scand J Public Health; 2010 Mar; 38(2):141-50. PubMed ID: 20064921
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility of repeated screening for Chlamydia trachomatis.
de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
Value Health; 2008; 11(2):272-4. PubMed ID: 18380639
[TBL] [Abstract][Full Text] [Related]
20. Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.
de Vries R; van Bergen JE; de Jong-van den Berg LT; Postma MJ;
Value Health; 2006; 9(1):1-11. PubMed ID: 16441519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
